Loading
A phase 3 trial of Inobrodib run by CellCentric Ltd., now recruiting.
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07772024 by CellCentric Ltd., with 450 participants planned, started 2026-08, primary completion expected 2029-11. Conditions recorded: Multiple Myeloma Refractory, Multiple Myeloma in Relapse. Interventions recorded: InoPd, Investigator's choice of SAT.
Shares Inobrodib, CellCentric, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Inobrodib, CellCentric and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/